Permeation enhancer-containing water-in-oil nanoemulsions as carriers for intravesical cisplatin delivery

Tsong Long Hwang, Chia Lang Fang, Chao Huang Chen, Jia You Fang

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: In the present work, we developed water-in-oil (w/o) nanoemulsions for the intravesical administration of cisplatin. Methods: The nanoemulsions were made up of soybean oil as the oil phase and Span 80, Tween 80, or Brij 98 as the emulsifier system. α-Terpineol and oleic acid were incorporated as permeation enhancers. The physicochemical characteristics of droplet size, zeta potential, and viscosity were determined. Nanoemulsions were administered intravesically for 1∈~∈4 h to rats in vivo. Animals were subsequently sacrificed, and the bladders were harvested to examine drug accumulation and histology. Results: Ranges of the mean size and zeta potential were 30∈~∈90 nm and -3.4 to -9.3 mV, respectively. The addition of enhancers further reduced the size of the nanoemulsions. The viscosity of all systems exhibited Newtonian behavior. The cisplatin-loaded nanoemulsions were active against bladder cancer cells. The nanoemulsions with Brij 98 exhibited the complete inhibition of cell proliferation. The encapsulation of cisplatin and carboplatin, another derivative of cisplatin, in nanoemulsions resulted in slower and more-sustained release. The amount of drug which permeated into bladder tissues significantly increased when using carriers containing Brij 98, with the α-terpineol-containing formulation showing the best result. The nanoemulsion with α-terpineol prolonged the duration of higher drug accumulation to 3∈~∈4 h. At the later stage of administration (3∈~∈4 h), this system increased the bladder wall deposition of cisplatin and carboplatin by 2.4∈~∈3.3-fold compared to the control solution. Histological examination of the urothelium showed near-normal morphology in rats instilled with these nanoemulsions. α-Terpineol possibly caused slight desquamation of umbrella cells. Conclusions: The nanoemulsions are feasible to load cisplatin for intravesical drug delivery.

Original languageEnglish
Pages (from-to)2314-2323
Number of pages10
JournalPharmaceutical Research
Volume26
Issue number10
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Permeation
Cisplatin
Oils
Water
Urinary Bladder
Carboplatin
Zeta potential
Viscosity
Pharmaceutical Preparations
Rats
Intravesical Administration
Urothelium
Soybean Oil
Histology
Polysorbates
Cell proliferation
Oleic Acid
Drug delivery
Encapsulation
Urinary Bladder Neoplasms

Keywords

  • Bladder
  • Cisplatin
  • Intravesical delivery
  • Nanoemulsion
  • Sustained release

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Organic Chemistry
  • Molecular Medicine
  • Pharmacology (medical)
  • Biotechnology
  • Pharmacology

Cite this

Permeation enhancer-containing water-in-oil nanoemulsions as carriers for intravesical cisplatin delivery. / Hwang, Tsong Long; Fang, Chia Lang; Chen, Chao Huang; Fang, Jia You.

In: Pharmaceutical Research, Vol. 26, No. 10, 10.2009, p. 2314-2323.

Research output: Contribution to journalArticle

Hwang, Tsong Long ; Fang, Chia Lang ; Chen, Chao Huang ; Fang, Jia You. / Permeation enhancer-containing water-in-oil nanoemulsions as carriers for intravesical cisplatin delivery. In: Pharmaceutical Research. 2009 ; Vol. 26, No. 10. pp. 2314-2323.
@article{92c072b16e2049079a5f8955a93a664b,
title = "Permeation enhancer-containing water-in-oil nanoemulsions as carriers for intravesical cisplatin delivery",
abstract = "Purpose: In the present work, we developed water-in-oil (w/o) nanoemulsions for the intravesical administration of cisplatin. Methods: The nanoemulsions were made up of soybean oil as the oil phase and Span 80, Tween 80, or Brij 98 as the emulsifier system. α-Terpineol and oleic acid were incorporated as permeation enhancers. The physicochemical characteristics of droplet size, zeta potential, and viscosity were determined. Nanoemulsions were administered intravesically for 1∈~∈4 h to rats in vivo. Animals were subsequently sacrificed, and the bladders were harvested to examine drug accumulation and histology. Results: Ranges of the mean size and zeta potential were 30∈~∈90 nm and -3.4 to -9.3 mV, respectively. The addition of enhancers further reduced the size of the nanoemulsions. The viscosity of all systems exhibited Newtonian behavior. The cisplatin-loaded nanoemulsions were active against bladder cancer cells. The nanoemulsions with Brij 98 exhibited the complete inhibition of cell proliferation. The encapsulation of cisplatin and carboplatin, another derivative of cisplatin, in nanoemulsions resulted in slower and more-sustained release. The amount of drug which permeated into bladder tissues significantly increased when using carriers containing Brij 98, with the α-terpineol-containing formulation showing the best result. The nanoemulsion with α-terpineol prolonged the duration of higher drug accumulation to 3∈~∈4 h. At the later stage of administration (3∈~∈4 h), this system increased the bladder wall deposition of cisplatin and carboplatin by 2.4∈~∈3.3-fold compared to the control solution. Histological examination of the urothelium showed near-normal morphology in rats instilled with these nanoemulsions. α-Terpineol possibly caused slight desquamation of umbrella cells. Conclusions: The nanoemulsions are feasible to load cisplatin for intravesical drug delivery.",
keywords = "Bladder, Cisplatin, Intravesical delivery, Nanoemulsion, Sustained release",
author = "Hwang, {Tsong Long} and Fang, {Chia Lang} and Chen, {Chao Huang} and Fang, {Jia You}",
year = "2009",
month = "10",
doi = "10.1007/s11095-009-9947-6",
language = "English",
volume = "26",
pages = "2314--2323",
journal = "Pharmaceutical Research",
issn = "0724-8741",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Permeation enhancer-containing water-in-oil nanoemulsions as carriers for intravesical cisplatin delivery

AU - Hwang, Tsong Long

AU - Fang, Chia Lang

AU - Chen, Chao Huang

AU - Fang, Jia You

PY - 2009/10

Y1 - 2009/10

N2 - Purpose: In the present work, we developed water-in-oil (w/o) nanoemulsions for the intravesical administration of cisplatin. Methods: The nanoemulsions were made up of soybean oil as the oil phase and Span 80, Tween 80, or Brij 98 as the emulsifier system. α-Terpineol and oleic acid were incorporated as permeation enhancers. The physicochemical characteristics of droplet size, zeta potential, and viscosity were determined. Nanoemulsions were administered intravesically for 1∈~∈4 h to rats in vivo. Animals were subsequently sacrificed, and the bladders were harvested to examine drug accumulation and histology. Results: Ranges of the mean size and zeta potential were 30∈~∈90 nm and -3.4 to -9.3 mV, respectively. The addition of enhancers further reduced the size of the nanoemulsions. The viscosity of all systems exhibited Newtonian behavior. The cisplatin-loaded nanoemulsions were active against bladder cancer cells. The nanoemulsions with Brij 98 exhibited the complete inhibition of cell proliferation. The encapsulation of cisplatin and carboplatin, another derivative of cisplatin, in nanoemulsions resulted in slower and more-sustained release. The amount of drug which permeated into bladder tissues significantly increased when using carriers containing Brij 98, with the α-terpineol-containing formulation showing the best result. The nanoemulsion with α-terpineol prolonged the duration of higher drug accumulation to 3∈~∈4 h. At the later stage of administration (3∈~∈4 h), this system increased the bladder wall deposition of cisplatin and carboplatin by 2.4∈~∈3.3-fold compared to the control solution. Histological examination of the urothelium showed near-normal morphology in rats instilled with these nanoemulsions. α-Terpineol possibly caused slight desquamation of umbrella cells. Conclusions: The nanoemulsions are feasible to load cisplatin for intravesical drug delivery.

AB - Purpose: In the present work, we developed water-in-oil (w/o) nanoemulsions for the intravesical administration of cisplatin. Methods: The nanoemulsions were made up of soybean oil as the oil phase and Span 80, Tween 80, or Brij 98 as the emulsifier system. α-Terpineol and oleic acid were incorporated as permeation enhancers. The physicochemical characteristics of droplet size, zeta potential, and viscosity were determined. Nanoemulsions were administered intravesically for 1∈~∈4 h to rats in vivo. Animals were subsequently sacrificed, and the bladders were harvested to examine drug accumulation and histology. Results: Ranges of the mean size and zeta potential were 30∈~∈90 nm and -3.4 to -9.3 mV, respectively. The addition of enhancers further reduced the size of the nanoemulsions. The viscosity of all systems exhibited Newtonian behavior. The cisplatin-loaded nanoemulsions were active against bladder cancer cells. The nanoemulsions with Brij 98 exhibited the complete inhibition of cell proliferation. The encapsulation of cisplatin and carboplatin, another derivative of cisplatin, in nanoemulsions resulted in slower and more-sustained release. The amount of drug which permeated into bladder tissues significantly increased when using carriers containing Brij 98, with the α-terpineol-containing formulation showing the best result. The nanoemulsion with α-terpineol prolonged the duration of higher drug accumulation to 3∈~∈4 h. At the later stage of administration (3∈~∈4 h), this system increased the bladder wall deposition of cisplatin and carboplatin by 2.4∈~∈3.3-fold compared to the control solution. Histological examination of the urothelium showed near-normal morphology in rats instilled with these nanoemulsions. α-Terpineol possibly caused slight desquamation of umbrella cells. Conclusions: The nanoemulsions are feasible to load cisplatin for intravesical drug delivery.

KW - Bladder

KW - Cisplatin

KW - Intravesical delivery

KW - Nanoemulsion

KW - Sustained release

UR - http://www.scopus.com/inward/record.url?scp=69949159301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949159301&partnerID=8YFLogxK

U2 - 10.1007/s11095-009-9947-6

DO - 10.1007/s11095-009-9947-6

M3 - Article

VL - 26

SP - 2314

EP - 2323

JO - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 10

ER -